Edwards Lifesciences (EW)

• Market cap: $43.2B
• 1 day: -1.89%
• 5 days: -3.81%
• 1 month: 4.76%
• 3 months: 4.15%
• 6 months: 4.58%
• Year to date: 0.98%
• 1 year: -15.41%
• 5 years: -4.90%
• 10 years: 227.52%
• Sector: Healthcare
• Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies

About: Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

Employees: 19,800

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

122% more call options, than puts

Call options by funds: $586M | Put options by funds: $264M

50% more funds holding in top 10

Funds holding in top 10: 6 [Q3] → 9 (+3) [Q4]

23% more first-time investments, than exits

New positions opened: 171 | Existing positions closed: 139

17% more capital invested

Capital invested by funds: $32B [Q3] → $37.3B (+$5.34B) [Q4]

4.4% more ownership

Funds ownership: 80.23% [Q3] → 84.63% (+4.4%) [Q4]

1% less funds holding

Funds holding: 1,176 [Q3] → 1,162 (-14) [Q4]

29% less repeat investments, than reductions

Existing positions increased: 340 | Existing positions reduced: 481

Research analyst outlook

12 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $60 18% downside
• Avg. target: $80 9% upside
• High target: $90 23% upside

12 analyst ratings

• positive: 6 50%
• neutral: 5 42%
• negative: 1 8%

Barclays Matt Miksic 72% 1-year accuracy 28 / 39 met price target	23% upside $90	Overweight Maintained	13 Feb 2025
Canaccord Genuity William Plovanic 67% 1-year accuracy 33 / 49 met price target	3% downside $71	Hold Maintained	13 Feb 2025
RBC Capital Shagun Singh 63% 1-year accuracy 44 / 70 met price target	16% upside $85	Outperform Reiterated	12 Feb 2025
Piper Sandler Adam Maeder 75% 1-year accuracy 12 / 16 met price target	0% downside $73	Neutral Maintained	12 Feb 2025
Evercore ISI Group Vijay Kumar 53% 1-year accuracy 25 / 47 met price target	0% downside $73	In-Line Maintained	12 Feb 2025